Miraparkin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole Dihydrochloride Monohydrate, the active ingredient in Miraparkin, is a dopamine agonist presented as an oral tablet for oral use. It is employed in the management of Parkinson's disease and restless legs syndrome, helping to improve motor function and reduce uncomfortable sensations in affected patients. It is approved for use across the European Union and is recognized for its efficacy in symptomatic control.

GNH USA supplies Miraparkin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Miraparkin (pramipexole) is a dopamine agonist used in movement‑disorder therapy.

- Parkinson's disease: improves motor function and reduces OFF periods in patients with idiopathic Parkinson's disease. - Restless legs syndrome: reduces the urge to move the legs and associated discomfort, improving sleep quality. - Adjunct therapy in Parkinson's disease: used alongside levodopa to enhance overall symptom control.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Impulse control disorders: compulsive gambling, shopping, or eating. - Hallucinations: visual or auditory disturbances. - Orthostatic hypotension: sudden drop in blood pressure upon standing. - Sudden sleep onset: unexpected episodes of falling asleep. - Severe depression or suicidal thoughts. - Allergic reactions: rash, swelling, or difficulty breathing.

Before initiating therapy, clinicians should consider several safety aspects.

- Assess renal function: dose may need adjustment in patients with impaired renal clearance. - Monitor for impulse control disorders: watch for compulsive behaviors during treatment. - Evaluate cardiovascular status: be cautious in individuals prone to orthostatic hypotension. - Avoid abrupt discontinuation: taper the dose to prevent withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Pramipexole may interact with several medication classes.

Major Interactions (Avoid): - MAO‑B inhibitors: combined use can precipitate hypertensive crises. - Dopamine antagonists (e.g., typical antipsychotics): may diminish therapeutic effect. - Strong CYP2D6 inhibitors (e.g., quinidine): can raise pramipexole plasma concentrations.

Moderate Interactions (Monitor Closely): - SSRIs or other serotonergic agents: may increase risk of serotonin syndrome. - Antihypertensive drugs: additive blood‑pressure‑lowering effect. - Other central nervous system depressants: may enhance sedation or dizziness.